EGFR haplotypes confer risk for tyrosine kinase domain mutations in non-small cell lung cancer

被引：0
|
作者：
Liu, Wanqing
He, Lijun
Krishnaswamy, Soundararajan
Kanteti, Rajani
Wang, Yi-Ching
Salgia, Ravi
Ratain, Mark
机构：
[1] Univ Chicago, Chicago, IL 60637 USA
[2] Natl Cheng Kung Univ, Tainan 701, Taiwan
来源：
CANCER RESEARCH | 2009年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3928
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Receptor tyrosine kinase mutations in non-small cell lung cancer
    Hayashi, H.
    Togashi, Y.
    Terashima, M.
    Sakai, K.
    Mizuuchi, H.
    Kobayashi, Y.
    Suda, K.
    Nakagawa, K.
    Nishio, K.
    Mitsudomi, T.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S601 - S601
  • [2] Impact of EGFR tyrosine kinase domain mutations on adjuvant chemotherapy in early stage non-small cell lung cancer (NSCLC)
    Tsao, Ming S.
    Sakurada, Akira
    Aviel-Ronen, Sarit
    Ding, Keyue
    Liu, Ni
    Gandara, David R.
    Johnson, David H.
    Rigas, James R.
    Seymour, Lesley
    Shepherd, Frances A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S351 - S352
  • [3] EGFR TYROSINE KINASE INHIBITOR USED IN NON-SMALL CELL LUNG CANCER
    Joshi, Pooja
    Singh, Anita
    Bisht, Dheeraj
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2020, 11 (03): : 1033 - 1041
  • [4] Radiosensitivity associated with EGFR tyrosine kinase domain mutations in non small cell lung carcinoma
    Avirneni, Usha
    Das, Amit
    Cho, Jae Ho
    Chen, Benjamin
    Chen, David
    Minna, John
    Nirodi, Chaitanya
    [J]. CANCER RESEARCH, 2009, 69
  • [5] Durable response to EGFR tyrosine kinase inhibitors in a patient with non-small cell lung cancer harboring an EGFR kinase domain duplication
    Hirokawa, Esuteru
    Watanabe, Satomi
    Sakai, Kazuko
    Takeda, Masayuki
    Sato, Chihiro
    Takahama, Takayuki
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    [J]. THORACIC CANCER, 2021, 12 (16) : 2283 - 2287
  • [6] Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer
    Yang, SH
    Mechanic, LE
    Yang, P
    Landi, MT
    Bowman, ED
    Wampfler, J
    Meerzaman, D
    Hong, KM
    Mann, F
    Dracheva, T
    Fukuoka, J
    Travis, W
    Caporaso, NE
    Harris, CC
    Jen, A
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (06) : 2106 - 2110
  • [7] Treatment outcomes with tyrosine kinase inhibitors in patients with uncommon EGFR mutations in non-small cell lung cancer
    Hunter, S.
    Nickless, G.
    Ghosh, S.
    Lal, R.
    Merrick, S. A.
    Montes, A.
    Smith, D.
    Spicer, J.
    Karapanagiotou, E.
    [J]. LUNG CANCER, 2017, 103 : S34 - S35
  • [8] Developing of EGFR resistant mutations to Tyrosine Kinase Inhibitors (TKI) in Non-Small Cell Lung Cancer (NSCLC)
    Raez, L. E.
    Baca, Y.
    Nagasaka, M.
    Nieva, J.
    Mandani, H.
    Wanderwalde, A.
    Borghaei, H.
    Naban, C.
    Langer, C.
    Socinsky, M. A.
    Lopes, G.
    Khan, H.
    Wozniak, A.
    Carracedo, C.
    Liu, S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S597 - S597
  • [9] EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
    Xiuning Le
    Eric Nadler
    Daniel B. Costa
    John Victor Heymach
    [J]. Targeted Oncology, 2023, 18 : 807 - 817
  • [10] EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC) with EGFR activating mutations - real world data
    Dulloo, Sean
    Almusarhed, Manar
    Chen, Ryan
    Akala, Oyeyemi
    Varadhan, Balaji
    Chauhan, Meera
    Ahmed, Samreen
    [J]. LUNG CANCER, 2021, 156 : S40 - S40
12345